Health written question – answered at on 11 November 2009.
To ask the Secretary of State for Health to what medicines which (a) have been appraised and (b) are under appraisal by the National Institute for Health and Clinical Excellence's supplementary advice on appraising treatments which may extend life, at the end of life, adopted on 17 December 2008, has been applied; what estimate he has made of the total annual eligible patient population for each indication for each such medicine; what the outcomes were of each completed appraisal; and if he will make a statement.
The information requested is in the following table.
Appraisal status | Appraisal title | Population (approx)( 1) | End of life criteria fulfilled for all or some of potentially eligible patient population | Recommendation |
Published | Sunitinib for the first line treatment of advanced and/or metastatic renal cell carcinoma | 4,000 | Yes | Partial recommendation |
Published | Lenalidomide for the treatment of multiple myeloma | 2,100 | Yes | Partial recommendation |
Published | Bevacizumab for the first-line treatment of advanced and/or metastatic renal cell carcinoma | 4,000 | Applicability considered by the appraisal committee but did not meet end of life criteria | Not Recommended |
Sorafenib for the first and second-line treatment of advanced and/or metastatic renal cell carcinoma | 4,000 | Yes | Not recommended | |
Sunitinib for the second-line treatment of advanced and/or metastatic renal cell carcinoma | 4,000 | Applicability considered by the appraisal committee but did not meet end of life criteria | Not recommended | |
Temsirolimus for the first-line treatment of advanced and/or metastatic renal cell carcinoma | 4,000 | Yes | Not recommended | |
Published | Sunitinib for the treatment of gastrointestinal stromal tumours | 150 | Yes | Partial recommendation |
Ongoing | Lapatinib for the treatment of breast cancer | 2,000 | Applicability considered by the appraisal committee but did not meet end of life criteria | Final guidance not yet issued |
Ongoing | Sorafenib for the treatment of hepatocellular carcinoma | Less than 1,000 | Yes | Final guidance not yet issued |
Ongoing | Trabectadin for soft tissue sarcoma | 500-600 | Yes | Final guidance not yet issued |
Ongoing | Azacitidine for myelodysplastic syndromes | 700 | Applicability considered by the appraisal committee but did not meet end of life criteria | Final guidance not yet issued |
(1) Approximate number of people annually with the condition. This will not necessarily represent the number of patients eligible for treatment with the drug. Source: |
Yes1 person thinks so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.